trastuzumab duocarmazine (Pending FDA Approval)

Brand and Other Names:
  • Print
Sections

Dosing & Uses

Breast Cancer

Pending FDA approval for HER2-positive unresectable locally advanced or metastatic breast cancer (MBC)

Next:

Pharmacology

Mechanism of Action

Antibody-drug conjugate (ADC); the ADC is comprised of the anti-HER2 monoclonal antibody trastuzumab and a cleavable linker-drug called valine-citrulline-seco-DUocarmycin-hydroxyBenzamide-Azaindole (vc-seco-DUBA)

Antibody portion binds to HER2 on the cancer cell surface and the ADC is internalized by the cell; after proteolytic cleavage of the linker, the inactive cytotoxin is activated and DNA damage is induced, resulting in tumor cell death

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.